Moreira-Andrés M N, Del Cañizo-Gómez F J, Black E G, Hoffenberg R
Clin Endocrinol (Oxf). 1981 Dec;15(6):621-6. doi: 10.1111/j.1365-2265.1981.tb00708.x.
Twenty obese patients were treated as out-patients with a 3.35 MJ (800 Kcal) per day diet, and, by the double-blind method, ten of the patients were prescribed 40 micrograms of triiodothyronine (T3) daily and the other ten placebo. Body weight and serum thyroxine (T4), T3 and reverse T3 (rT3) concentrations were measured before treatment, then monthly over 6 months. No significant difference in mean weight loss was found between the patients receiving T3 and those on placebo. Serum T3 concentration decreased slightly in patients on placebo and increased in those on T3 but these changes were not statistically significant. However, patients on T3 maintained a significantly higher concentration of T3 in serum than those on placebo. Mean serum T4 and rT3 concentrations remained essentially unchanged in the patients on placebo, whereas both decreased significantly in patients receiving T3. We conclude that changes in serum T3 during dietary treatment of obesity are of minor significance in limiting the expected weight loss in the patients.
20名肥胖患者作为门诊病人接受每日3.35兆焦耳（800千卡）饮食治疗，采用双盲法，其中10名患者每日服用40微克三碘甲状腺原氨酸（T3），另外10名患者服用安慰剂。在治疗前、治疗后的6个月内每月测量体重以及血清甲状腺素（T4）、T3和反三碘甲状腺原氨酸（rT3）浓度。接受T3治疗的患者与服用安慰剂的患者在平均体重减轻方面未发现显著差异。服用安慰剂的患者血清T3浓度略有下降，服用T3的患者血清T3浓度有所上升，但这些变化无统计学意义。然而，服用T3的患者血清T3浓度显著高于服用安慰剂的患者。服用安慰剂的患者血清T4和rT3平均浓度基本保持不变，而接受T3治疗的患者血清T4和rT3浓度均显著下降。我们得出结论，在肥胖症饮食治疗期间血清T3的变化对限制患者预期体重减轻的意义不大。
